Patients with high free prostate-specific antibodies are less likely to be diagnosed with prostate cancer.
Prostate-specific antigen is a glycoprotein synthesized by prostate epithelial cells. Prostate-specific antigen exists in two forms in plasma, most of which are bound to plasma proteins, while a small portion exists in a free state as free prostate-specific antibodies.
Prostate-specific antibody is a tumor marker for clinical screening and early diagnosis of prostate cancer, and the proportion of free prostate-specific antibody is often used to determine the likelihood of prostate cancer. The lower the free prostate-specific antibodies, the higher the likelihood of prostate cancer, and the lower the total prostate-specific antibodies, the higher the likelihood of prostate cancer.
When the total prostate-specific antigen is in the gray zone, i.e., 4-10 ng/ml, the free prostate-specific antibodies are high and the patient is less likely to be diagnosed with prostate cancer. If the total prostate-specific antigen is more than 10ng/ml, the value of free prostate-specific antigen is not significant.
It is recommended that the patient should go to the hospital in time, do some relevant examinations, and if necessary, need to undergo prostate aspiration biopsy in order to clarify whether there is prostate cancer.